Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 2: 194 - 200

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.02.008

Clinical research

Effect of intraoperative use of low-dose dexmedetomidine on the prognosis of patients undergoing breast cancer surgery

  • Xiaoxuan YANG ,
  • Shan ZHU ,
  • Cheng QIAN ,
  • Xiaoying CHU
Expand
  • Department of Anesthesiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
CHU Xiaoying, E-mail: shirleychu@sina.com.

Received date: 2022-11-15

  Accepted date: 2023-01-18

  Online published: 2023-02-28

Fold

Abstract

Objective ·To investigate the influence of intraoperative dexmedetomidine infusion on the recurrence-free survival (RFS) and overall survival (OS) rate of patients undergoing breast cancer surgery. Methods ·A retrospective analysis was performed on patients who underwent breast cancer surgery at the Breast Disease Diagnosis and Treatment Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from July 2013 to June 2014. Patients were divided into dexmedetomidine group and control group according to whether dexmedetomidine was injected intraoperatively at 0.7?0.8 ìg/kg. After correcting the confounding factors between the two groups by using the propensity score matching method, the factors affecting the prognosis and survival of patients undertaking breast cancer surgery were investigated by univariate and multivariate analysis, and the Kaplan-Meier survival curve was further used to analyze the effect of intraoperative dexmedetomidine on RFS and OS after five years of breast cancer surgery. Results ·There were significant differences in age, progesterone receptor (PR) positive ratio, proliferating cell nuclear antigen (Ki67) expression score, American Society of Anesthesiologists (ASA) grade, and anesthesia duration between the two groups before propensity score matching. After propensity score matching, a total of 239 pairs were successfully matched, and there was no significant difference in baseline data and perioperative data between the two groups (P>0.05). Univariate analysis showed that age (P=0.032), postoperative radiotherapy (P=0.041), Ki67 score (P=0.021), and tumor TMN stage (P=0.029) were significantly correlated with postoperative five-year OS. The results of multivariate analysis showed that postoperative radiotherapy, Ki67 score, and tumor TMN stage were significantly correlated with postoperative five-year OS (P<0.05). Intraoperative low-dose dexmedetomidine infusion was not a risk factor for postoperative five-year OS (P>0.05). Compared with the control group, the five-year postoperative RFS and OS in dexmedetomidine group did not decrease significantly (P>0.05). Conclusion ·Intraoperative use of low dosage of dexmedetomidine (0.7?0.8 μg/kg) has no significant effect on RFS and OS in patients undergoing breast cancer surgery at five years postoperatively, providing theoretical reference for the rational selection of anesthetics for tumor patients. The effect of higher dosage of dexmedetomidine needs to be further confirmed by prospective multicenter randomized controlled studies.

Key words： dexmedetomidine; breast cancer; overall survival; recurrence-free survival

Cite this article

Xiaoxuan YANG , Shan ZHU , Cheng QIAN , Xiaoying CHU . Effect of intraoperative use of low-dose dexmedetomidine on the prognosis of patients undergoing breast cancer surgery[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(2) : 194 -200 . DOI: 10.3969/j.issn.1674-8115.2023.02.008

References

1 BALASUBRAMANIAN R, ROLPH R, MORGAN C, et al. Genetics of breast cancer: management strategies and risk-reducing surgery[J]. Br J Hosp Med (Lond), 2019, 80(12): 720-725.
2 WANG Y L, XU X F, LIU H, et al. Effects of dexmedetomidine on patients undergoing radical gastrectomy[J]. J Surg Res, 2015, 194(1): 147-153.
3 CATA J P, SINGH V, LEE B M, et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery[J]. J Anaesthesiol Clin Pharmacol, 2017, 33(3): 317-323.
4 WANG C Y, DATOO T, ZHAO H L, et al. Midazolam and dexmedetomidine affect neuroglioma and lung carcinoma cell biology in vitro and in vivo[J]. Anesthesiology, 2018, 129(5): 1000-1014.
5 LAVON H, MATZNER P, BENBENISHTY A, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers[J]. Br J Anaesth, 2018, 120(1): 188-196.
6 SZPUNAR M J, BURKE K A, DAWES R P, et al. The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure[J]. Cancer Prev Res (Phila), 2013, 6(12): 1262-1272.
7 LIU Y, SUN J X, WU T, et al. Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: a prospective randomized controlled trial[J]. Cancer Med, 2019, 8(18): 7603-7612.
8 VON MINCKWITZ G, SCHMITT W D, LOIBL S, et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer[J]. Clin Cancer Res, 2013, 19(16): 4521-4531.
9 CHEN X S, ZHU S J, FEI X C, et al. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients[J]. BMC Cancer, 2015, 15: 822.
10 CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2): 115-132.
11 FLANDERS C A, ROCKE A S, EDWARDSON S A, et al. The effect of dexmedetomidine and clonidine on the inflammatory response in critical illness: a systematic review of animal and human studies[J]. Crit Care, 2019, 23(1): 402.
12 VáZQUEZ S M, MLADOVAN A G, PéREZ C, et al. Human breast cell lines exhibit functional α2-adrenoceptors[J]. Cancer Chemother Pharmacol, 2006, 58(1): 50-61.
13 XIA M, TONG J H, ZHOU Z Q, et al. Tramadol inhibits proliferation, migration and invasion via α2-adrenoceptor signaling in breast cancer cells[J]. Eur Rev Med Pharmacol Sci, 2016, 20(1): 157-165.
14 ZHENG L H, ZHAO J, ZHENG L K, et al. Effect of dexmedetomidine on perioperative stress response and immune function in patients with tumors[J]. Technol Cancer Res Treat, 2020, 19: 1533033820977542.
15 LAVON H, KRIGMAN R, ELBAZ E, et al. The perioperative use of the sedative dexmedetomidine in cancer patients may have detrimental effects[J]. Brain Behav Immun, 2015, 49: e29.
16 MANNE G R, UPADHYAY M R, SWADIA V. Effects of low dose dexmedetomidine infusion on haemodynamic stress response, sedation and post-operative analgesia requirement in patients undergoing laparoscopic cholecystectomy[J]. Indian J Anaesth, 2014, 58(6): 726-731.
17 SIOBAL M S, KALLET R H, KIVETT V A, et al. Use of dexmedetomidine to facilitate extubation in surgical intensive-care-unit patients who failed previous weaning attempts following prolonged mechanical ventilation: a pilot study[J]. Respir Care, 2006, 51(5): 492-496.
18 温润耀. TCH新辅助化疗方案对HER2阳性乳腺癌的疗效及对患者ER、PR、HER2表达的影响[J]. 中国医学创新, 2021, 18(13): 15-19.
18 WEN R Y. Influence of efficacy and levels of ER, PR, HER2 in HER2 positive breast cancer by TCH neoadjuvant chemotherapy regimen[J]. Medical Innovation of China, 2021, 18(13): 15-19.
Options
Outlines

/

〈 〉